Blue Jet Healthcare Limited (BLUEJET.BO) Stock Competitors & Peer Comparison
See (BLUEJET.BO) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| BLUEJET.BO | ₹512.65 | +0.32% | 88.9B | 35.90 | ₹14.28 | +0.23% |
| BIOCON.BO | ₹415.70 | +0.50% | 568.7B | 146.89 | ₹2.83 | +0.12% |
| BIOCON.NS | ₹415.50 | +0.40% | 568.1B | 146.82 | ₹2.83 | +0.12% |
| ANTHEM.NS | ₹791.05 | -0.88% | 444.3B | 75.55 | ₹10.47 | N/A |
| ONESOURCE.NS | ₹1,608.60 | -2.58% | 184.4B | -251.34 | -₹6.40 | N/A |
| SYNGENE.NS | ₹440.75 | +0.10% | 177.1B | 55.93 | ₹7.88 | +0.28% |
| SYNGENE.BO | ₹440.90 | +0.11% | 177B | 55.88 | ₹7.89 | +0.28% |
| CONCORDBIO.BO | ₹1,316.55 | -1.90% | 138B | 53.22 | ₹24.74 | +0.81% |
| CONCORDBIO.NS | ₹1,315.10 | -2.40% | 137.6B | 53.14 | ₹24.75 | +0.81% |
| BLUEJET.NS | ₹512.60 | +0.33% | 88.9B | 35.87 | ₹14.29 | +0.23% |
Stock Comparison
BLUEJET.BO vs BIOCON.BO Comparison June 2026
BLUEJET.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUEJET.BO stands at 88.9B. In comparison, BIOCON.BO has a market cap of 568.7B. Regarding current trading prices, BLUEJET.BO is priced at ₹512.65, while BIOCON.BO trades at ₹415.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUEJET.BO currently has a P/E ratio of 35.90, whereas BIOCON.BO's P/E ratio is 146.89. In terms of profitability, BLUEJET.BO's ROE is +0.20%, compared to BIOCON.BO's ROE of +0.01%. Regarding short-term risk, BLUEJET.BO is more volatile compared to BIOCON.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BLUEJET.BO.Check BIOCON.BO's competition here
BLUEJET.BO vs BIOCON.NS Comparison June 2026
BLUEJET.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUEJET.BO stands at 88.9B. In comparison, BIOCON.NS has a market cap of 568.1B. Regarding current trading prices, BLUEJET.BO is priced at ₹512.65, while BIOCON.NS trades at ₹415.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUEJET.BO currently has a P/E ratio of 35.90, whereas BIOCON.NS's P/E ratio is 146.82. In terms of profitability, BLUEJET.BO's ROE is +0.20%, compared to BIOCON.NS's ROE of +0.01%. Regarding short-term risk, BLUEJET.BO is more volatile compared to BIOCON.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BLUEJET.BO.Check BIOCON.NS's competition here
BLUEJET.BO vs ANTHEM.NS Comparison June 2026
BLUEJET.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUEJET.BO stands at 88.9B. In comparison, ANTHEM.NS has a market cap of 444.3B. Regarding current trading prices, BLUEJET.BO is priced at ₹512.65, while ANTHEM.NS trades at ₹791.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUEJET.BO currently has a P/E ratio of 35.90, whereas ANTHEM.NS's P/E ratio is 75.55. In terms of profitability, BLUEJET.BO's ROE is +0.20%, compared to ANTHEM.NS's ROE of +0.22%. Regarding short-term risk, BLUEJET.BO is less volatile compared to ANTHEM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for BLUEJET.BO.Check ANTHEM.NS's competition here
BLUEJET.BO vs ONESOURCE.NS Comparison June 2026
BLUEJET.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUEJET.BO stands at 88.9B. In comparison, ONESOURCE.NS has a market cap of 184.4B. Regarding current trading prices, BLUEJET.BO is priced at ₹512.65, while ONESOURCE.NS trades at ₹1,608.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUEJET.BO currently has a P/E ratio of 35.90, whereas ONESOURCE.NS's P/E ratio is -251.34. In terms of profitability, BLUEJET.BO's ROE is +0.20%, compared to ONESOURCE.NS's ROE of -0.01%. Regarding short-term risk, BLUEJET.BO is less volatile compared to ONESOURCE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for BLUEJET.BO.Check ONESOURCE.NS's competition here
BLUEJET.BO vs SYNGENE.NS Comparison June 2026
BLUEJET.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUEJET.BO stands at 88.9B. In comparison, SYNGENE.NS has a market cap of 177.1B. Regarding current trading prices, BLUEJET.BO is priced at ₹512.65, while SYNGENE.NS trades at ₹440.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUEJET.BO currently has a P/E ratio of 35.90, whereas SYNGENE.NS's P/E ratio is 55.93. In terms of profitability, BLUEJET.BO's ROE is +0.20%, compared to SYNGENE.NS's ROE of +0.07%. Regarding short-term risk, BLUEJET.BO is more volatile compared to SYNGENE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BLUEJET.BO.Check SYNGENE.NS's competition here
BLUEJET.BO vs SYNGENE.BO Comparison June 2026
BLUEJET.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUEJET.BO stands at 88.9B. In comparison, SYNGENE.BO has a market cap of 177B. Regarding current trading prices, BLUEJET.BO is priced at ₹512.65, while SYNGENE.BO trades at ₹440.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUEJET.BO currently has a P/E ratio of 35.90, whereas SYNGENE.BO's P/E ratio is 55.88. In terms of profitability, BLUEJET.BO's ROE is +0.20%, compared to SYNGENE.BO's ROE of +0.07%. Regarding short-term risk, BLUEJET.BO is more volatile compared to SYNGENE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BLUEJET.BO.Check SYNGENE.BO's competition here
BLUEJET.BO vs CONCORDBIO.BO Comparison June 2026
BLUEJET.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUEJET.BO stands at 88.9B. In comparison, CONCORDBIO.BO has a market cap of 138B. Regarding current trading prices, BLUEJET.BO is priced at ₹512.65, while CONCORDBIO.BO trades at ₹1,316.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUEJET.BO currently has a P/E ratio of 35.90, whereas CONCORDBIO.BO's P/E ratio is 53.22. In terms of profitability, BLUEJET.BO's ROE is +0.20%, compared to CONCORDBIO.BO's ROE of +0.14%. Regarding short-term risk, BLUEJET.BO is less volatile compared to CONCORDBIO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BLUEJET.BO.Check CONCORDBIO.BO's competition here
BLUEJET.BO vs CONCORDBIO.NS Comparison June 2026
BLUEJET.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUEJET.BO stands at 88.9B. In comparison, CONCORDBIO.NS has a market cap of 137.6B. Regarding current trading prices, BLUEJET.BO is priced at ₹512.65, while CONCORDBIO.NS trades at ₹1,315.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUEJET.BO currently has a P/E ratio of 35.90, whereas CONCORDBIO.NS's P/E ratio is 53.14. In terms of profitability, BLUEJET.BO's ROE is +0.20%, compared to CONCORDBIO.NS's ROE of +0.14%. Regarding short-term risk, BLUEJET.BO is less volatile compared to CONCORDBIO.NS. This indicates potentially lower risk in terms of short-term price fluctuations for BLUEJET.BO.Check CONCORDBIO.NS's competition here
BLUEJET.BO vs BLUEJET.NS Comparison June 2026
BLUEJET.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUEJET.BO stands at 88.9B. In comparison, BLUEJET.NS has a market cap of 88.9B. Regarding current trading prices, BLUEJET.BO is priced at ₹512.65, while BLUEJET.NS trades at ₹512.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUEJET.BO currently has a P/E ratio of 35.90, whereas BLUEJET.NS's P/E ratio is 35.87. In terms of profitability, BLUEJET.BO's ROE is +0.20%, compared to BLUEJET.NS's ROE of +0.20%. Regarding short-term risk, BLUEJET.BO is more volatile compared to BLUEJET.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BLUEJET.BO.Check BLUEJET.NS's competition here
BLUEJET.BO vs SUPRIYA.NS Comparison June 2026
BLUEJET.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUEJET.BO stands at 88.9B. In comparison, SUPRIYA.NS has a market cap of 75B. Regarding current trading prices, BLUEJET.BO is priced at ₹512.65, while SUPRIYA.NS trades at ₹932.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUEJET.BO currently has a P/E ratio of 35.90, whereas SUPRIYA.NS's P/E ratio is 35.92. In terms of profitability, BLUEJET.BO's ROE is +0.20%, compared to SUPRIYA.NS's ROE of +0.20%. Regarding short-term risk, BLUEJET.BO is less volatile compared to SUPRIYA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for BLUEJET.BO.Check SUPRIYA.NS's competition here
BLUEJET.BO vs SUPRIYA.BO Comparison June 2026
BLUEJET.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUEJET.BO stands at 88.9B. In comparison, SUPRIYA.BO has a market cap of 75B. Regarding current trading prices, BLUEJET.BO is priced at ₹512.65, while SUPRIYA.BO trades at ₹931.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUEJET.BO currently has a P/E ratio of 35.90, whereas SUPRIYA.BO's P/E ratio is 35.85. In terms of profitability, BLUEJET.BO's ROE is +0.20%, compared to SUPRIYA.BO's ROE of +0.20%. Regarding short-term risk, BLUEJET.BO is less volatile compared to SUPRIYA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BLUEJET.BO.Check SUPRIYA.BO's competition here
BLUEJET.BO vs ZOTA.NS Comparison June 2026
BLUEJET.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUEJET.BO stands at 88.9B. In comparison, ZOTA.NS has a market cap of 39.7B. Regarding current trading prices, BLUEJET.BO is priced at ₹512.65, while ZOTA.NS trades at ₹1,307.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUEJET.BO currently has a P/E ratio of 35.90, whereas ZOTA.NS's P/E ratio is -58.22. In terms of profitability, BLUEJET.BO's ROE is +0.20%, compared to ZOTA.NS's ROE of -0.21%. Regarding short-term risk, BLUEJET.BO is less volatile compared to ZOTA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for BLUEJET.BO.Check ZOTA.NS's competition here
BLUEJET.BO vs PANACEABIO.NS Comparison June 2026
BLUEJET.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUEJET.BO stands at 88.9B. In comparison, PANACEABIO.NS has a market cap of 32.9B. Regarding current trading prices, BLUEJET.BO is priced at ₹512.65, while PANACEABIO.NS trades at ₹536.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUEJET.BO currently has a P/E ratio of 35.90, whereas PANACEABIO.NS's P/E ratio is -618.16. In terms of profitability, BLUEJET.BO's ROE is +0.20%, compared to PANACEABIO.NS's ROE of -0.01%. Regarding short-term risk, BLUEJET.BO is less volatile compared to PANACEABIO.NS. This indicates potentially lower risk in terms of short-term price fluctuations for BLUEJET.BO.Check PANACEABIO.NS's competition here
BLUEJET.BO vs PANACEABIO.BO Comparison June 2026
BLUEJET.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUEJET.BO stands at 88.9B. In comparison, PANACEABIO.BO has a market cap of 32.9B. Regarding current trading prices, BLUEJET.BO is priced at ₹512.65, while PANACEABIO.BO trades at ₹535.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUEJET.BO currently has a P/E ratio of 35.90, whereas PANACEABIO.BO's P/E ratio is -608.35. In terms of profitability, BLUEJET.BO's ROE is +0.20%, compared to PANACEABIO.BO's ROE of -0.01%. Regarding short-term risk, BLUEJET.BO is less volatile compared to PANACEABIO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BLUEJET.BO.Check PANACEABIO.BO's competition here
BLUEJET.BO vs DCAL.NS Comparison June 2026
BLUEJET.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUEJET.BO stands at 88.9B. In comparison, DCAL.NS has a market cap of 26.8B. Regarding current trading prices, BLUEJET.BO is priced at ₹512.65, while DCAL.NS trades at ₹170.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUEJET.BO currently has a P/E ratio of 35.90, whereas DCAL.NS's P/E ratio is 27.45. In terms of profitability, BLUEJET.BO's ROE is +0.20%, compared to DCAL.NS's ROE of +0.02%. Regarding short-term risk, BLUEJET.BO is less volatile compared to DCAL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for BLUEJET.BO.Check DCAL.NS's competition here
BLUEJET.BO vs DCAL.BO Comparison June 2026
BLUEJET.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUEJET.BO stands at 88.9B. In comparison, DCAL.BO has a market cap of 26.7B. Regarding current trading prices, BLUEJET.BO is priced at ₹512.65, while DCAL.BO trades at ₹170.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUEJET.BO currently has a P/E ratio of 35.90, whereas DCAL.BO's P/E ratio is 27.42. In terms of profitability, BLUEJET.BO's ROE is +0.20%, compared to DCAL.BO's ROE of +0.02%. Regarding short-term risk, BLUEJET.BO is less volatile compared to DCAL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BLUEJET.BO.Check DCAL.BO's competition here
BLUEJET.BO vs TITANBIO.BO Comparison June 2026
BLUEJET.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUEJET.BO stands at 88.9B. In comparison, TITANBIO.BO has a market cap of 17.9B. Regarding current trading prices, BLUEJET.BO is priced at ₹512.65, while TITANBIO.BO trades at ₹434.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUEJET.BO currently has a P/E ratio of 35.90, whereas TITANBIO.BO's P/E ratio is 60.21. In terms of profitability, BLUEJET.BO's ROE is +0.20%, compared to TITANBIO.BO's ROE of +0.18%. Regarding short-term risk, BLUEJET.BO is less volatile compared to TITANBIO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BLUEJET.BO.Check TITANBIO.BO's competition here
BLUEJET.BO vs 3BBLACKBIO.BO Comparison June 2026
BLUEJET.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUEJET.BO stands at 88.9B. In comparison, 3BBLACKBIO.BO has a market cap of 10.3B. Regarding current trading prices, BLUEJET.BO is priced at ₹512.65, while 3BBLACKBIO.BO trades at ₹1,198.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUEJET.BO currently has a P/E ratio of 35.90, whereas 3BBLACKBIO.BO's P/E ratio is 17.14. In terms of profitability, BLUEJET.BO's ROE is +0.20%, compared to 3BBLACKBIO.BO's ROE of +0.20%. Regarding short-term risk, BLUEJET.BO is less volatile compared to 3BBLACKBIO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BLUEJET.BO.Check 3BBLACKBIO.BO's competition here
BLUEJET.BO vs FERMENTA.BO Comparison June 2026
BLUEJET.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUEJET.BO stands at 88.9B. In comparison, FERMENTA.BO has a market cap of 9.7B. Regarding current trading prices, BLUEJET.BO is priced at ₹512.65, while FERMENTA.BO trades at ₹338.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUEJET.BO currently has a P/E ratio of 35.90, whereas FERMENTA.BO's P/E ratio is 13.79. In terms of profitability, BLUEJET.BO's ROE is +0.20%, compared to FERMENTA.BO's ROE of +0.19%. Regarding short-term risk, BLUEJET.BO is less volatile compared to FERMENTA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BLUEJET.BO.Check FERMENTA.BO's competition here
BLUEJET.BO vs KILPEST.BO Comparison June 2026
BLUEJET.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUEJET.BO stands at 88.9B. In comparison, KILPEST.BO has a market cap of 6.3B. Regarding current trading prices, BLUEJET.BO is priced at ₹512.65, while KILPEST.BO trades at ₹808.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUEJET.BO currently has a P/E ratio of 35.90, whereas KILPEST.BO's P/E ratio is 18.32. In terms of profitability, BLUEJET.BO's ROE is +0.20%, compared to KILPEST.BO's ROE of N/A. Regarding short-term risk, BLUEJET.BO is less volatile compared to KILPEST.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BLUEJET.BO.Check KILPEST.BO's competition here
BLUEJET.BO vs SMSLIFE.BO Comparison June 2026
BLUEJET.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUEJET.BO stands at 88.9B. In comparison, SMSLIFE.BO has a market cap of 4.5B. Regarding current trading prices, BLUEJET.BO is priced at ₹512.65, while SMSLIFE.BO trades at ₹1,478.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUEJET.BO currently has a P/E ratio of 35.90, whereas SMSLIFE.BO's P/E ratio is 23.89. In terms of profitability, BLUEJET.BO's ROE is +0.20%, compared to SMSLIFE.BO's ROE of +0.08%. Regarding short-term risk, BLUEJET.BO is more volatile compared to SMSLIFE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BLUEJET.BO.Check SMSLIFE.BO's competition here
BLUEJET.BO vs HALEOSLABS.BO Comparison June 2026
BLUEJET.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUEJET.BO stands at 88.9B. In comparison, HALEOSLABS.BO has a market cap of 4.5B. Regarding current trading prices, BLUEJET.BO is priced at ₹512.65, while HALEOSLABS.BO trades at ₹1,478.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUEJET.BO currently has a P/E ratio of 35.90, whereas HALEOSLABS.BO's P/E ratio is 25.83. In terms of profitability, BLUEJET.BO's ROE is +0.20%, compared to HALEOSLABS.BO's ROE of +0.09%. Regarding short-term risk, BLUEJET.BO is more volatile compared to HALEOSLABS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BLUEJET.BO.Check HALEOSLABS.BO's competition here
BLUEJET.BO vs TAKE.NS Comparison June 2026
BLUEJET.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUEJET.BO stands at 88.9B. In comparison, TAKE.NS has a market cap of 4.4B. Regarding current trading prices, BLUEJET.BO is priced at ₹512.65, while TAKE.NS trades at ₹30.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUEJET.BO currently has a P/E ratio of 35.90, whereas TAKE.NS's P/E ratio is 103.55. In terms of profitability, BLUEJET.BO's ROE is +0.20%, compared to TAKE.NS's ROE of +0.44%. Regarding short-term risk, BLUEJET.BO is less volatile compared to TAKE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for BLUEJET.BO.Check TAKE.NS's competition here
BLUEJET.BO vs TAKE.BO Comparison June 2026
BLUEJET.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUEJET.BO stands at 88.9B. In comparison, TAKE.BO has a market cap of 4.4B. Regarding current trading prices, BLUEJET.BO is priced at ₹512.65, while TAKE.BO trades at ₹30.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUEJET.BO currently has a P/E ratio of 35.90, whereas TAKE.BO's P/E ratio is 103.45. In terms of profitability, BLUEJET.BO's ROE is +0.20%, compared to TAKE.BO's ROE of +0.44%. Regarding short-term risk, BLUEJET.BO is less volatile compared to TAKE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BLUEJET.BO.Check TAKE.BO's competition here
BLUEJET.BO vs HALEOSLABS.NS Comparison June 2026
BLUEJET.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUEJET.BO stands at 88.9B. In comparison, HALEOSLABS.NS has a market cap of 4.3B. Regarding current trading prices, BLUEJET.BO is priced at ₹512.65, while HALEOSLABS.NS trades at ₹1,410.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUEJET.BO currently has a P/E ratio of 35.90, whereas HALEOSLABS.NS's P/E ratio is 24.60. In terms of profitability, BLUEJET.BO's ROE is +0.20%, compared to HALEOSLABS.NS's ROE of +0.09%. Regarding short-term risk, BLUEJET.BO is less volatile compared to HALEOSLABS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for BLUEJET.BO.Check HALEOSLABS.NS's competition here
BLUEJET.BO vs SMSLIFE.NS Comparison June 2026
BLUEJET.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUEJET.BO stands at 88.9B. In comparison, SMSLIFE.NS has a market cap of 3.9B. Regarding current trading prices, BLUEJET.BO is priced at ₹512.65, while SMSLIFE.NS trades at ₹1,299.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUEJET.BO currently has a P/E ratio of 35.90, whereas SMSLIFE.NS's P/E ratio is 21.01. In terms of profitability, BLUEJET.BO's ROE is +0.20%, compared to SMSLIFE.NS's ROE of +0.10%. Regarding short-term risk, BLUEJET.BO is more volatile compared to SMSLIFE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BLUEJET.BO.Check SMSLIFE.NS's competition here
BLUEJET.BO vs LYKALABS.NS Comparison June 2026
BLUEJET.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUEJET.BO stands at 88.9B. In comparison, LYKALABS.NS has a market cap of 2.4B. Regarding current trading prices, BLUEJET.BO is priced at ₹512.65, while LYKALABS.NS trades at ₹67.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUEJET.BO currently has a P/E ratio of 35.90, whereas LYKALABS.NS's P/E ratio is -23.98. In terms of profitability, BLUEJET.BO's ROE is +0.20%, compared to LYKALABS.NS's ROE of -0.10%. Regarding short-term risk, BLUEJET.BO is less volatile compared to LYKALABS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for BLUEJET.BO.Check LYKALABS.NS's competition here
BLUEJET.BO vs LYKALABS.BO Comparison June 2026
BLUEJET.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUEJET.BO stands at 88.9B. In comparison, LYKALABS.BO has a market cap of 2.4B. Regarding current trading prices, BLUEJET.BO is priced at ₹512.65, while LYKALABS.BO trades at ₹67.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUEJET.BO currently has a P/E ratio of 35.90, whereas LYKALABS.BO's P/E ratio is 115.10. In terms of profitability, BLUEJET.BO's ROE is +0.20%, compared to LYKALABS.BO's ROE of -0.10%. Regarding short-term risk, BLUEJET.BO is less volatile compared to LYKALABS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BLUEJET.BO.Check LYKALABS.BO's competition here
BLUEJET.BO vs ALFAVIO.BO Comparison June 2026
BLUEJET.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUEJET.BO stands at 88.9B. In comparison, ALFAVIO.BO has a market cap of 260.7M. Regarding current trading prices, BLUEJET.BO is priced at ₹512.65, while ALFAVIO.BO trades at ₹8.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUEJET.BO currently has a P/E ratio of 35.90, whereas ALFAVIO.BO's P/E ratio is 206.75. In terms of profitability, BLUEJET.BO's ROE is +0.20%, compared to ALFAVIO.BO's ROE of +0.00%. Regarding short-term risk, BLUEJET.BO is less volatile compared to ALFAVIO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BLUEJET.BO.Check ALFAVIO.BO's competition here
BLUEJET.BO vs TRABI.BO Comparison June 2026
BLUEJET.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUEJET.BO stands at 88.9B. In comparison, TRABI.BO has a market cap of 239.4M. Regarding current trading prices, BLUEJET.BO is priced at ₹512.65, while TRABI.BO trades at ₹3.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUEJET.BO currently has a P/E ratio of 35.90, whereas TRABI.BO's P/E ratio is -14.36. In terms of profitability, BLUEJET.BO's ROE is +0.20%, compared to TRABI.BO's ROE of -0.18%. Regarding short-term risk, BLUEJET.BO is less volatile compared to TRABI.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BLUEJET.BO.Check TRABI.BO's competition here
BLUEJET.BO vs SAMSRITA.BO Comparison June 2026
BLUEJET.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUEJET.BO stands at 88.9B. In comparison, SAMSRITA.BO has a market cap of 188.2M. Regarding current trading prices, BLUEJET.BO is priced at ₹512.65, while SAMSRITA.BO trades at ₹12.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUEJET.BO currently has a P/E ratio of 35.90, whereas SAMSRITA.BO's P/E ratio is -3.19. In terms of profitability, BLUEJET.BO's ROE is +0.20%, compared to SAMSRITA.BO's ROE of -0.64%. Regarding short-term risk, BLUEJET.BO is less volatile compared to SAMSRITA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BLUEJET.BO.Check SAMSRITA.BO's competition here
BLUEJET.BO vs VANTABIO.BO Comparison June 2026
BLUEJET.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUEJET.BO stands at 88.9B. In comparison, VANTABIO.BO has a market cap of 177.3M. Regarding current trading prices, BLUEJET.BO is priced at ₹512.65, while VANTABIO.BO trades at ₹24.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUEJET.BO currently has a P/E ratio of 35.90, whereas VANTABIO.BO's P/E ratio is 166.20. In terms of profitability, BLUEJET.BO's ROE is +0.20%, compared to VANTABIO.BO's ROE of -0.17%. Regarding short-term risk, BLUEJET.BO is less volatile compared to VANTABIO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BLUEJET.BO.Check VANTABIO.BO's competition here
BLUEJET.BO vs STARSOURCE.BO Comparison June 2026
BLUEJET.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUEJET.BO stands at 88.9B. In comparison, STARSOURCE.BO has a market cap of 149M. Regarding current trading prices, BLUEJET.BO is priced at ₹512.65, while STARSOURCE.BO trades at ₹99.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUEJET.BO currently has a P/E ratio of 35.90, whereas STARSOURCE.BO's P/E ratio is -1.26. In terms of profitability, BLUEJET.BO's ROE is +0.20%, compared to STARSOURCE.BO's ROE of -0.93%. Regarding short-term risk, BLUEJET.BO is more volatile compared to STARSOURCE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BLUEJET.BO.Check STARSOURCE.BO's competition here
BLUEJET.BO vs GVBL.BO Comparison June 2026
BLUEJET.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUEJET.BO stands at 88.9B. In comparison, GVBL.BO has a market cap of 97.3M. Regarding current trading prices, BLUEJET.BO is priced at ₹512.65, while GVBL.BO trades at ₹31.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUEJET.BO currently has a P/E ratio of 35.90, whereas GVBL.BO's P/E ratio is 318.50. In terms of profitability, BLUEJET.BO's ROE is +0.20%, compared to GVBL.BO's ROE of -0.01%. Regarding short-term risk, BLUEJET.BO is more volatile compared to GVBL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BLUEJET.BO.Check GVBL.BO's competition here
BLUEJET.BO vs SERVOTEACH.BO Comparison June 2026
BLUEJET.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUEJET.BO stands at 88.9B. In comparison, SERVOTEACH.BO has a market cap of 0. Regarding current trading prices, BLUEJET.BO is priced at ₹512.65, while SERVOTEACH.BO trades at ₹20.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUEJET.BO currently has a P/E ratio of 35.90, whereas SERVOTEACH.BO's P/E ratio is N/A. In terms of profitability, BLUEJET.BO's ROE is +0.20%, compared to SERVOTEACH.BO's ROE of +0.00%. Regarding short-term risk, BLUEJET.BO is less volatile compared to SERVOTEACH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BLUEJET.BO.Check SERVOTEACH.BO's competition here